Subscribe to news

Press Releases

03.04.2014
The Human Stem Cells Institute, one of Russia’s leading biotech companies, announces the results of its Extraordinary General Shareholders’ Meeting (EGSM).
03.04.2014
The Human Stem Cells Institute, one of Russia’s leading biotech companies, today announced its audited unconsolidated results for 2013 in accordance with the Russian Accounting Standards (RAS)
07.03.2014
The Human Stem Cells Institute, today announced the decision of its Board of Directors on the lists of candidates to the Board of Directors and the Audit Commission of the Company to be elected at the Annual General Shareholders’ Meeting.
19.02.2014
The Human Stem Cells Institute, announces the signing of an investment agreement with RVC Biofund.
18.02.2014
Human Stem Cells Institute (HSCI), one of Russia's leading biotech companies (MOEX: ISKJ ), announcedthe transfer of its share in the charter capital of SynBio LLC to the IceGen LLC in the form of an additional contribution to the charter capital of the latter.
14.02.2014
OJSC HSCI, today announces that the Ministry of Industry and Trade of the Russian Federation has issued the Human Stem Cells Institute (HSCI) a license “To engage in the production of medicinal products” (No.12785-LS-P dated 31 December 2013).
14.01.2014
OJSC HSCI, one of Russia’s leading biotech companies specializing in cell-based, gene and post-genome technologies, today announces a change in the company’s shareholding structure.
04.12.2013
OJSC HSCI, one of Russia’s leading biotech companies specializing in cell-based, gene and post-genome technologies, today announced its ordinary shares to be included in the Broad Market Index and the Second-Tier Index of the Moscow Exchange.
15.11.2013
OJSC HSCI – The Human Stem Cells Institute (“HSCI”, MOEX: ISKJ), one of Russia’s leading biotech companies specializing in cell-based, gene and post-genome technologies, today announced its unaudited unconsolidated results for the first nine months of 2013 in accordance with the Russian Accounting Standards (RAS)
30.08.2013
OJSC HSCI – The Human Stem Cells Institute (“HSCI”, MICEX: ISKJ), one of Russia’s leading biotech companies specializing in cell-based, gene and post-genome technologies, today announced its unaudited consolidated interim results for the first half of 2013 (6 months ended June 30, 2013) under International Financial Reporting Standards (IFRS)